## Marcello Galvani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/429655/publications.pdf

Version: 2024-02-01

105 papers 24,447 citations

39 h-index 29157 104 g-index

112 all docs

112 docs citations

112 times ranked

23877 citing authors

#	Article	IF	CITATIONS
1	Balloon aortic valvuloplasty: current status and future prospects. Expert Review of Cardiovascular Therapy, 2022, 20, 389-402.	1.5	2
2	Transcatheter aortic valve implantation for severe pure aortic regurgitation due to active aortitis. Catheterization and Cardiovascular Interventions, 2021, 97, 950-954.	1.7	1
3	In- and out-of-hospital mortality for myocardial infarction during the first wave of the COVID-19 pandemic in Emilia-Romagna, Italy: A population-based observational study. Lancet Regional Health - Europe, The, 2021, 3, 100055.	5.6	36
4	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. Lancet Haematology,the, 2021, 8, e627-e636.	4.6	11
5	Early Resolution of Heyde's Syndrome following Transcatheter Aortic Valve Replacement. Seminars in Thrombosis and Hemostasis, 2021, 47, 102-104.	2.7	3
6	The Assessment of Scales of Frailty and Physical Performance Improves Prediction of Major Adverse Cardiac Events in Older Adults with Acute Coronary Syndrome. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1113-1119.	3.6	49
7	Electrocardiographic features of 431 consecutive, critically ill COVID-19 patients: an insight into the mechanisms of cardiac involvement. Europace, 2020, 22, 1848-1854.	1.7	74
8	Integration of the Universal Definition of Myocardial Infarction into administrative data. Journal of Cardiovascular Medicine, 2020, 21, 40-41.	1.5	0
9	Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy. New England Journal of Medicine, 2020, 383, 88-89.	27.0	873
10	Gender differences in acute coronary syndromes patterns during the COVID-19 outbreak. American Journal of Cardiovascular Disease, 2020, 10, 506-513.	0.5	1
11	Multimodality Imaging of Purulent Pericarditis: Hints to Speed up Diagnosis and Promote Healing. Journal of Invasive Cardiology, 2020, 32, E79-E80.	0.4	0
12	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 618-628.	11.4	207
13	Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study. Cardiovascular Drugs and Therapy, 2019, 33, 523-532.	2.6	11
14	Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation. JAMA Cardiology, 2019, 4, 526.	6.1	26
15	Stroke prevention in patients from Latin American countries with nonâ€valvular atrial fibrillation: Insights from the GARFIELDâ€AF registry. Clinical Cardiology, 2019, 42, 553-560.	1.8	16
16	Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF. American Heart Journal, 2019, 213, 35-46.	2.7	45
17	Management and 1‥ear Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. Journal of the American Heart Association, 2019, 8, e010510.	3.7	44
18	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. American Journal of Cardiovascular Drugs, 2019, 19, 173-183.	2.2	23

#	Article	IF	CITATIONS
19	Rapid rule-out of suspected acute coronary syndrome in the Emergency Department by high-sensitivity cardiac troponin T levels at presentation. Internal and Emergency Medicine, 2019, 14, 403-410.	2.0	3
20	Cardiac Arrest in a 31-Year-Old Man With Noonan Syndrome. Journal of Invasive Cardiology, 2019, 31, E40.	0.4	0
21	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. European Heart Journal, 2018, 39, 464-473.	2.2	28
22	Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial. International Journal of Cardiology, 2018, 255, 8-14.	1.7	1
23	High-sensitivity troponin in emergency room practice. Journal of Cardiovascular Medicine, 2018, 19, e68-e71.	1.5	6
24	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 205-218.	13.7	426
25	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229.	13.7	651
26	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. New England Journal of Medicine, 2018, 379, 2097-2107.	27.0	2,211
27	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. Indian Heart Journal, 2018, 70, 828-835.	0.5	16
28	Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS ONE, 2018, 13, e0191592.	2.5	80
29	Reperfusion in STEMI patients: still a role for cardioprotection?. Minerva Cardiology and Angiology, 2018, 66, 452-463.	0.7	9
30	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart, 2017, 103, 307-314.	2.9	205
31	Impact of gender on event rates at 1â€year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open, 2017, 7, e014579.	1.9	30
32	Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. International Journal of Cardiology, 2017, 244, 59-66.	1.7	21
33	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	27.0	1,745
34	Patients with non-ST segment elevation acute coronary syndromes managed without coronary revascularization: A population needing treatment improvement. International Journal of Cardiology, 2017, 245, 35-42.	1.7	6
35	Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention. Data in Brief, 2017, 14, 197-205.	1.0	13

Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Postâ∈Hoc Analysis of the GISSIâ∈HF (Gruppo Italiano per lo Studio della Sopravvivenza nella) Tj ETQqO 0307rgBT /O50€rlock 10

3

36

#	Article	IF	CITATIONS
37	The frailty in elderly patients receiving cardiac interventional procedures (FRASER) program: rational and design of a multicenter prospective study. Aging Clinical and Experimental Research, 2017, 29, 895-903.	2.9	19
38	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. BMJ Open, 2017, 7, e017157.	1.9	92
39	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. British Journal of Haematology, 2016, 174, 610-623.	2.5	13
40	Effect of Pre-Hospital Ticagrelor During the FirstÂ24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2016, 9, 646-656.	2.9	31
41	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. European Heart Journal, 2016, 37, 2882-2889.	2.2	222
42	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS ONE, 2016, 11, e0164076.	2.5	118
43	Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S12-20.	2.2	74
44	Sex-Related Outcomes in Elderly Patients Presenting With Non–ST-Segment Elevation Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2015, 8, 791-796.	2.9	39
45	Regular Wine Consumption in Chronic Heart Failure. Circulation: Heart Failure, 2015, 8, 428-437.	3.9	26
46	Which is the best catheter to perform atrial fibrillation ablation? A comparison between standard ThermoCool, SmartTouch, and Surround Flow catheters. Journal of Interventional Cardiac Electrophysiology, 2014, 39, 193-200.	1.3	36
47	A false positive case of cardiac troponin I: Which diagnostic approach?. International Journal of Cardiology, 2014, 177, e42-e43.	1.7	4
48	Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. Journal of Invasive Cardiology, 2014, 26, 563-9.	0.4	24
49	Documento de consenso de expertos. Tercera definición universal del infarto de miocardio. Revista Espanola De Cardiologia, 2013, 66, 132.e1-132.e15.	1.2	18
50	Proposal for the use in emergency departments of cardiac troponins measured with the latest generation methods in patients with suspected acute coronary syndrome without persistent ST-segment elevation. Clinical Chemistry and Laboratory Medicine, 2013, 51, 1727-37.	2.3	41
51	How to use C-reactive protein in acute coronary care. European Heart Journal, 2013, 34, 3687-3690.	2.2	22
52	Proposal for the use in emergency departments of cardiac troponins measured with the latest generation methods in patients with suspected acute coronary syndrome without persistent ST-segment elevation. Emergency Care Journal, 2013, 9, 14.	0.3	0
53	In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. Journal of Invasive Cardiology, 2013, 25, 170-6.	0.4	8
54	The prognostic value of plasma fibrinogen concentrations of patients with ST-elevation myocardial infarction and treated by primary percutaneous coronary intervention: A cautionary message. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 355-362.	1.2	4

#	Article	IF	CITATIONS
55	Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization. New England Journal of Medicine, 2012, 367, 1297-1309.	27.0	765
56	Third Universal Definition of Myocardial Infarction. Circulation, 2012, 126, 2020-2035.	1.6	2,722
57	Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of copeptin. Clinical Chemistry and Laboratory Medicine, 2012, 50, 243-53.	2.3	34
58	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	2.2	2,447
59	Ultra-sensitive troponin I levels to exclude acute myocardial infarction from myocardial injury. Clinical Chemistry and Laboratory Medicine, 2012, 50, 159-66.	2.3	3
60	Recommendations for the use of natriuretic peptides in acute cardiac care: A position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. European Heart Journal, 2012, 33, 2001-2006.	2.2	233
61	Predicting unfavorable outcome in subjects with diagnosis of chest pain of undifferentiated origin. American Journal of Emergency Medicine, 2012, 30, 61-67.	1.6	3
62	How to use high-sensitivity cardiac troponins in acute cardiac care. European Heart Journal, 2012, 33, 2252-2257.	2.2	666
63	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	2.8	2,558
64	Atrial fibrillation after typical atrial flutter ablation: a long-term follow-up. Journal of Cardiovascular Medicine, 2011, 12, 110-115.	1.5	17
65	Comparison by Meta-Analysis of Eptifibatide and Tirofiban to Abciximab in Patients With ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2010, 106, 167-174.e1.	1.6	28
66	Recommendations for the use of cardiac troponin measurement in acute cardiac care. European Heart Journal, 2010, 31, 2197-2204.	2.2	533
67	A prospective multicentre observational study on the management of patients on oral anticoagulation undergoing coronary artery stenting: rationale and design of the ongoing warfarin and coronary stenting (WAR-STENT) registry. Journal of Cardiovascular Medicine, 2009, 10, 200-203.	1.5	10
68	Early aggressive vs. initially conservative treatment in elderly patients with non-ST-elevation acute coronary syndrome: The Italian Elderly ACS study. Journal of Cardiovascular Medicine, 2008, 9, 217-226.	1.5	12
69	Cardiomyopathy induced by adenosine-insensitive atrial tachycardia. Journal of Cardiovascular Medicine, 2008, 9, 1147-1151.	1.5	2
70	Universal Definition of Myocardial Infarction. Circulation, 2007, 116, 2634-2653.	1.6	2,755
71	Low-Molecular-Weight Heparins in Conjunction with Thrombolysis for ST-Elevation Acute Myocardial Infarction. Cardiology, 2007, 107, 132-139.	1.4	6
72	High postclopidogrel platelet reactivity in non-ST-elevation acute coronary syndrome treated with stenting: a clue for adverse prognosis?. Journal of Thrombosis and Haemostasis, 2006, 4, 536-538.	3.8	2

#	Article	IF	CITATIONS
73	Monitoring intervention programmes for out-of-hospital cardiac arrest in a mixed urban and rural setting. Resuscitation, 2006, 71, 180-187.	3.0	32
74	Acute Cardiac Care: Apocalypse Now!. Acute Cardiac Care, 2006, 8, 4-6.	0.2	1
75	Prodromal Angina Limits Infarct Size in the Setting of Acute Anterior Myocardial Infarction Treated With Primary Percutaneous Intervention. Journal of the American College of Cardiology, 2005, 45, 1545-1547.	2.8	19
76	N-Terminal Pro-Brain Natriuretic Peptide on Admission Has Prognostic Value Across the Whole Spectrum of Acute Coronary Syndromes. Circulation, 2004, 110, 128-134.	1.6	281
77	Natriuretic peptides for risk stratification of patients with acute coronary syndromes. European Journal of Heart Failure, 2004, 6, 327-333.	7.1	87
78	Therapeutic strategies, immediate and mid-term outcomes in non-ST-segment elevation acute coronary syndromes with respect to age: A single-center registry of 488 consecutive patients. Clinical Cardiology, 2004, 27, 475-479.	1.8	5
79	Clinical significance of a single measurement of troponin-I and C-reactive protein at admission in 1773 consecutive patients with acute coronary syndromes. American Heart Journal, 2004, 148, 405-415.	2.7	29
80	Coagulation activation and long-term outcome in acute coronary syndromes. Blood, 2003, 102, 2731-2735.	1.4	95
81	The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. Journal of the American College of Cardiology, 2002, 39, 22-29.	2.8	43
82	Cardiac markers and risk stratification: an integrated approach. Clinica Chimica Acta, 2001, 311, 9-17.	1.1	15
83	Prognostic role of hemostatic markers in acute coronary syndromes patients. Clinica Chimica Acta, 2001, 311, 33-39.	1.1	26
84	Soluble E-selectin is not a marker of unstable coronary plaque in serum of patients with ischemic heart disease. Journal of Thrombosis and Thrombolysis, 2000, 9, 53-60.	2.1	14
85	In Vivo Thrombin Generation and Activity During and After Intravenous Infusion of Heparin or Recombinant Hirudin in Patients With Unstable Angina Pectoris. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 2162-2166.	2.4	25
86	Myocardial infarction redefined—A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. European Heart Journal, 2000, 21, 1502-1513.	2.2	1,444
87	lt's Time for a Change to a Troponin Standard. Circulation, 2000, 102, 1216-1220.	1.6	584
88	Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. American Heart Journal, 2000, 140, 917-927.	2.7	232
89	Are Cardiac Troponins the Myocardial Markers for the New Millenium?. Clinical Chemistry and Laboratory Medicine, 1999, 37, 605-6.	2.3	1
90	Direct comparison of early elevations of cardiac troponin T and I in patients with clinical unstable angina. American Heart Journal, 1999, 137, 284-291.	2.7	41

#	Article	IF	CITATIONS
91	Early risk stratification of unstable angina/non-Q myocardial infarction: biochemical markers of coronary thrombosis. International Journal of Cardiology, 1999, 68, S55-S61.	1.7	16
92	Clinical relevance of prodromal angina before acute myocardial infarction. International Journal of Cardiology, 1999, 68, S103-S108.	1.7	11
93	New markers for early diagnosis of acute myocardial infarction. International Journal of Cardiology, 1998, 65, S17-S22.	1.7	6
94	The importance of antibody specificity in measuring cross-linked fibrin degradation products by ELISA. Blood Coagulation and Fibrinolysis, 1997, 8, 105-113.	1.0	7
95	Prognostic Influence of Elevated Values of Cardiac Troponin I in Patients With Unstable Angina. Circulation, 1997, 95, 2053-2059.	1.6	277
96	Conjunctive Administration of Intravenous Heparin Attenuates Cross-linked Fibrin Degradation in Patients Treated with Streptokinase. Thrombosis and Haemostasis, 1996, 76, 339-343.	3.4	1
97	Non-invasive assessment of reperfusion of the infarct-related artery during coronary thrombolysis and its relation with left ventricular function. International Journal of Cardiology, 1995, 49, S59-S69.	1.7	4
98	Prodromal Angina Limits Infarct Size. Circulation, 1995, 91, 291-297.	1.6	341
99	Concurrent nitroglycerin therapy impairs tissue-type plasminogen activator-induced thrombolysis in patients with acute myocardial infarction. American Journal of Cardiology, 1994, 74, 662-666.	1.6	19
100	Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. Journal of the American College of Cardiology, 1994, 24, 1445-1452.	2.8	38
101	Patency of the infarct-related artery and left ventricular function as the major determinants of survival after Q-wave acute myocardial infarction. American Journal of Cardiology, 1993, 71, 1-7.	1.6	94
102	Myocardial ischemia during intravenous prostacyclin administration: Hemodynamic findings and precautionary measures. American Heart Journal, 1987, 113, 234-240.	2.7	35
103	Effects of iloprost, a stable prostacyclin analog, on exercise capacity and platelet aggregation in stable angina pectoris. American Journal of Cardiology, 1986, 58, 453-459.	1.6	53
104	Myocardial ischemia induced by prostacyclin and iloprost. Clinical Pharmacology and Therapeutics, 1985, 38, 101-108.	4.7	51
105	Side effects of prostacyclin in patients with angina pectoris and coronary artery disease. Research in Clinic and Laboratory, 1985, 15, 145-149.	0.3	1